YC-1, a nitric oxide-independent activator of soluble guanylate cyclase, inhibits platelet-rich thrombosis in mice

European Journal of Pharmacology

Volumn 320, Issue 2-3, 1997, Pages 161-166

  Teng, Che Ming ^a   Wu, Chin Chung ^a   Ko, Feng Nien ^a   Lee, Fang Yu ^b   Kuo, Sheng Chu ^c  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b Yung Shin Pharmaceutical Industry Co Ltd   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Antithrombotic effect; Platelet aggregation; Profibrinolytic effect; Tail bleeding time; YC 1 (3 (5' hydroxymethyl 2' furyl) 1 benzylindazole)

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; GUANYLATE CYCLASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING TIME; BLOOD CLOT LYSIS; CONTROLLED STUDY; DRUG EFFECT; EUGLOBULIN LYSIS TEST; FIBRINOLYSIS; INTRAPERITONEAL DRUG ADMINISTRATION; LUNG EMBOLISM; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOSIS;

ADENOSINE DIPHOSPHATE; ANIMALS; BLEEDING TIME; BLOOD COAGULATION; BLOOD PLATELETS; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; FIBRINOLYTIC AGENTS; FLUORESCEIN; FLUORESCEINS; GUANYLATE CYCLASE; INDAZOLES; MALE; MICE; MICE, INBRED ICR; NITRIC OXIDE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PULMONARY EMBOLISM; SERUM GLOBULINS; SOLUBILITY; THROMBOSIS;

EID: 0031565271     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(96)00911-9     Document Type: Article

References (35)

1. Antiplatelet Trialists' Collaboration, 1994a, Collaborative overview of randomized trials of antiplatelet therapy I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients, Br. Med. J. 308, 81.
2. Antiplatelet Trialists' Collaboration, 1994b, Collaborative overview of randomized trials of antiplatelet therapy II: maintenance of vascular graft or arterial patency by antiplatelet therapy, Br. Med. J. 308, 159.
3. Basista, M., L. Grodzinska and J. Swies, 1985, The influence of molsidomine and its active metabolite SIN-1 on fibrinolysis and platelet aggregation, Thromb. Haemost. 54, 746.
4. Beviglia, L., A. Poggi, C. Rossi, M.A. McLane, R. Calabrese, E. Scanziani, J.J. Cook and S. Niewiarowski, 1993, Mouse antithrombotic assay. Inhibition of platelet thrombolism by disintegrins, Thromb. Res. 71, 301.
5. Chang, M.C. and T.F. Huang, 1994, In vivo effect of a thrombin-like enzyme on platelet plug formation induced in mesenteric microvessels of mice, Thromb. Res. 73, 31.
6. Coller, B.S., 1990, Platelet and thrombolytic therapy, New Engl. J. Med. 322, 33.
7. Coller, B.S., 1992, Antiplatelet agents in the prevention and therapy of thrombosis, Annu. Rev. Med. 43, 171.
8. Cook, J.J., T.F. Huang, B. Rucinski, M. Strzyzewski, R.F. Tuma, J.A. Williams and S. Niewiarowski, 1989, Inhibition of platelet hemostatic plug formation by trigramin, a novel RGD-peptide, Am. J. Physiol. 256, H1038.
9. Dejana, E., S. Villa and G. De Gaetano, 1982, Bleeding time in rats: a comparison of different experimental conditions, Thromb. Haemost. 48, 108.
10. Dinerman, J.L. and J.L. Mehta, 1990, Endothelial, platelet and leukocyte interactions in ischemic heart disease: Insights into potential mechanisms and their clinical relevance, J. Am. Coll. Cardiol. 16, 207.
11. Drummer, C., S. Ludke, M. Spannagl, W. Schramm and R. Gerzer, 1991, The nitric oxide donor SIN-1 is a potent inhibitor of plasminogen activator inhibitor release from stimulated platelets, Thromb. Res. 62, 553.
12. Fareed, J., P. Bacher, H.L. Messmore, J.M. Walenga, D.A. Hoppensteadt, A. Strano and R. Pifarre, 1992, Pharmacological modulation of fibrinolysis by anti-thrombotic and cardiovascular drugs, Prog. Cardiovasc. Dis. 34, 379.
13. Fay, W.P., D.T. Eitzman, A.D. Shapiro, E.L. Madison and D. Ginsburg, 1994, Platelets inhibit fibrinolysis in vitro by both plasminogen activator inhibitor-1-dependent and -independent mechanisms, Blood 83, 351.
14. Huang, T.F., J.C. Holt, H. Lukasiewicz and S. Niewiarowski, 1987, Trigramin. A low molecule weight peptide inhibiting fibrinogen interaction with platelet receptors expressed on glycoprotein IIb-IIIa complex, J. Biol. Chem. 262, 16157.
15. Ko, F.N., C.C. Wu, S.C. Kuo, F.Y. Lee and C.M. Teng, 1994, YC-1, a novel activator of platelet guanylate cyclase, Blood 84, 4226.
16. Levi, M., B.J. Biemond, A.J. Van Zonneveld, J.W. Ten Cate and H. Pannekoek, 1992, Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis, Circulation 85, 305.
17. Lidbury, P.S., R. Korbut and J.R. Vane, 1990, Sodium nitroprusside modulate the fibrinolytic system in the rabbit, Br. J. Pharmacol. 101, 527.
18. Lindberg, R.A., D.W. Slaaf, A.B. Lentsch and F.N. Miller, 1994, Involvement of nitric oxide and cyclooxygenase products in photoactivation-induced microvascular occlusion, Microvasc. Res. 47, 203.
19. Nordoy, A. and A.B. Chandler, 1964, Platelet thrombosis induced by adenosine diphosphate in the rat, Scand. J. Haematol. 1, 16.
20. O'Brien, J.R., 1962, Platelet aggregation II. Some results from a new method of study, J. Clin. Pathol. 15, 452.
21. Rosenblum, W.I. and F. El-Sabban, 1977, Platelet aggregation in the cerebral microcirculation: effect of aspirin and other agents, Circ. Res. 40, 320.
22. Ross, R., 1993, The pathogenesis of atherosclerosis: a perspective for the 1990s, Nature 362, 801.
23. Sato, M. and N. Ohshima, 1984, Platelet thrombus induced in vivo by filtered light and fluorescent dye in mesenteric microvessels of the rat, Thromb. Res. 35, 319.
24. Schwortz, S.M., R.L. Heimark and M.W. Majesky, 1990, Developmental mechanisms underlying pathology of arteries, Physiol. Rev. 70, 1177.
25. Sheu, J.R., S.H. Chao, M.H. Yen and T.F. Huang, 1994, In vivo antithrombotic effect of triflavin, an Arg-Gly-Asp containing peptide on platelet plug formation in mesenteric microvessels of mice, Thromb. Haemost. 72, 617.
26. Sheu, J.R., M.H. Yen, H.C. Peng, M.C. Chang and T.F. Huang, 1995, Triflavin, an Arg-Gly-Asp-containing peptide, prevents platelet plug formation in in vivo experiments, Eur. J. Pharmacol. 294, 231.
27. Stamler, J.S., 1994, Redox signaling: nitrosylation and related target interactions of nitric oxide, Cell 78, 931.
28. Stamler, J.S., D.I. Simon, O. Jaraki, J.A. Osborne, S. Francis, M. Mullins, D. Singel and J. Loscalzo, 1992, S-Nitrosylation of tissue-type plasminogen activator confers vasodilatory and antiplatelet properties on the enzyme, Proc. Natl. Acad. Sci. USA, 89, 8087.
29. Stringer, H.A.R., P. Van Swieten, H.F.G. Heijnen, J.J. Sixma and H. Pannekoek, 1994, Plasminogen activator inhibitor-1 released from activated platelets plays a key role in thrombolysis resistance, Arterioscler. Thromb. 14, 1452.
30. Suehiro, A., Y. Oura, M. Ueda and E. Kakishita, 1994, Correlation between bleeding time and antithrombotic effect of platelet-suppressive agents in rat experimental model, Res. Commun. Chem. Pathol. Pharmacol. 83, 157.
31. The EPIC Investigators, 1994, Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty, New Engl. J. Med. 330, 956.
32. Von Kaulla, K.N. and R.L. Schultz, 1958, Methods for evaluation of human fibrinolysis, Am. J. Clin. Pathol. 29, 104.
33. Wu, C.C., F.N. Ko, S.C. Kuo, F.Y. Lee and C.M. Teng, 1995, YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase, Br. J. Pharmacol. 116, 1973.
34. Yoshina, S. and S.C. Kuo, 1978, Studies on heterocyclic compounds. XXXV. Synthesis of fuo[3,3-C]pyrazole derivatives. (2) electrophilic substitution of 1,3-diphenylfuro[3,2-C] pyrazole, Yakugaku Zasshi 98, 204.
35. Yu, S.M., Z.J. Cheng, J.H. Guh, F.Y. Lee and S.C. Kuo, 1995, Mechanism of anti-proliferation caused by YC-1, an indazole derivative, in cultured rat A10 vascular smooth muscle cells, Biochem. J. 306, 787.